Weekly shot could help shed pounds in obesity trial

NCT ID NCT07648225

Not yet recruiting Disease control Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 study tests whether a weekly injection called UBT251 can help overweight or obese adults lose weight. Participants receive either the drug or a placebo for 52 weeks. The main goal is to measure the percentage change in body weight, with additional checks on waist size, BMI, and blood pressure. The trial includes adults aged 18-75 with a BMI of 24 or higher who also have conditions like prediabetes, high blood pressure, or fatty liver.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UBT251 injection
What this could lead to: If successful, this could offer a new weekly injection option for significant weight loss in people with obesity or overweight who have related health issues.
What could go wrong: This is a phase 3 trial, but results may not apply to everyone. Side effects are possible, and the drug may not work as well in real-world settings or for all participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT

Contacts and locations

Locations

Peking University People's Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.